Thomas Schmelter

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Combination Therapy

Age Related Macular Degeneration

Optical Coherence Tomography

Top Venues

Advances in therapy

Journal of vitreoretinal diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Laurent Kodjikian, Lluís Arias Barquet, András Papp, Peter J Kertes, Edoardo Midena, Jan Ernest, Rufino Silva, Thomas Schmelter, Tobias Niesen, Sergio Leal
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing. Advances in therapy 41 (3) (2024)
Laurent Kodjikian, Lluís Arias Barquet, András Papp, Peter J Kertes, Edoardo Midena, Jan Ernest, Rufino Silva, Thomas Schmelter, Tobias Niesen, Sergio Leal
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing. Advances in therapy 41 (3) (2024)
Laurent Kodjikian, Lluís Arias Barquet, András Papp, Peter J Kertes, Edoardo Midena, Jan Ernest, Rufino Silva, Thomas Schmelter, Tobias Niesen, Sergio Leal
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing. Advances in therapy 41 (3) (2024)
Laurent Kodjikian, Lluís Arias Barquet, András Papp, Peter J Kertes, Edoardo Midena, Jan Ernest, Rufino Silva, Thomas Schmelter, Tobias Niesen, Sergio Leal
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing. Advances in therapy (2024)
Laurent Kodjikian, Lluís Arias Barquet, András Papp, Peter J Kertes, Edoardo Midena, Jan Ernest, Rufino Silva, Thomas Schmelter, Tobias Niesen, Sergio Leal
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing. Advances in therapy 41 (3) (2024)
Laurent Kodjikian, Lluís Arias Barquet, András Papp, Peter J Kertes, Edoardo Midena, Jan Ernest, Rufino Silva, Thomas Schmelter, Tobias Niesen, Sergio Leal
Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing. Advances in therapy 41 (3) (2024)
Jeffrey S Heier, Allen C Ho, David S Boyer, Karl Csaky, Robert Vitti, Lorah Perlee, Karen W Chu, Friedrich Asmus, Sergio Leal, Oliver Zeitz, Yenchieh Cheng, Thomas Schmelter, David M Brown
Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial. Journal of vitreoretinal diseases 7 (1) (2022)